BackIovance Biotherapeutics Overview

Iovance Biotherapeutics Total Current Liabilities

Latest total current liabilities for IOVA: $110M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$106.85M
17.27% YoYΔ $-22.31M vs prior year quarter

Peer average / median

Loading

Iovance Biotherapeutics Total Current Liabilities History

Loading

Iovance Biotherapeutics vs. peers: Total Current Liabilities Comparison

Loading

Iovance Biotherapeutics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Iovance Biotherapeutics (IOVA) FAQ

As of the most recent data (June 2026), IOVA shows a total current liabilities of $110M. That compares with $130M in the prior-year period — down 17.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IOVA's total current liabilities is now $110M (was $130M) — a 17.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Iovance Biotherapeutics is outperforming or lagging.

Tracking IOVA's total current liabilities over time shows whether Iovance Biotherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $110M That compares with $130M in the prior-year period — down 17.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Iovance Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $110M) with ownership activity and broader fundamentals.

Iovance Biotherapeutics's total current liabilities is $110M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.